Genes May Determine Cancer Drug's Effectiveness
20th Dec 2005, 02:26 GMT
Researchers have discovered a genetic difference that explains why some breast cancer patients don't respond to a drug that otherwise has been effective in keeping cancer from returning. Tamoxifen has been credited with reducing by one-third the death rates of women with hormone-sensitive breast cancer, the most common type. Typically, premenopausal women take the drug for five years after surgery.
Genes May Determine Cancer Drug's Effectiveness related news:
- [Medical_Sciences] Human cancers overexpress genes that are specific to a variety of normal human tissues — Proceedings of the National Academy of Sciences recent issues
- Body backs Sanofi's Taxotere in prostate cancer — KeralaNext: Business
- Gene May Undermine Tamoxifen's Effectiveness (HealthDay) — Yahoo! News: Health News
- New cancer drug to get clinical trials in New Zealand. — Daily New Zealand News
- Kidney cancer drug gets FDA approval — USATODAY.com Health - Top Stories
- Tamiflu's effectiveness questioned as two bird flu victims develop drug-resistance — The Earth Times Online Newspaper - Health News
- US approves new drug for advanced kidney cancer (Reuters) — Yahoo! News: Health News
- FDA approves new kidney cancer drug (Reuters) — Yahoo! News: Health News
- Mayo Clinic finds kidney cancer patients are unlikely to respond to potential treatment drug — EurekAlert! - Cancer
- Aromatase inhibitor shows promise for breast cancer patients — The Cancer Blog
Latest news from TechNewsWorld:
- Novell's Deal With the Devil, Mac Malware, High-Def Gaming
- Is Legal Trouble Brewing for Microsoft and Novell?
- IBM's Blue Gene/L Tops List of Fastest Computers
- Sony's PS3 Nifty, But Price Is No Fun
- Samsung Expects Strong Q4 Sales
- Deutsche Telekom Names T-Mobile Head New CEO
- Inventors Create 'Stairway to Heaven' In a Shirt
- Project Seeks to Speed Heart Attack Care
- Nintendo Unleashes $200 Million Wii Ad Campaign
- Sun Opens Java to Developers